行情

AKBA

AKBA

Akebia
NASDAQ

实时行情|Nasdaq Last Sale

6.73
-0.34
-4.81%
盘后: 6.73 0 0.00% 17:01 04/03 EDT
开盘
7.01
昨收
7.07
最高
7.14
最低
6.55
成交量
81.21万
成交额
--
52周最高
10.53
52周最低
2.990
市值
8.74亿
市盈率(TTM)
-2.8501
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测AKBA价格均价为15.04,最高价位23.00,最低价为8.00。

EPS

AKBA 新闻

更多
  • Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • PR Newswire · 2天前
  • Is the Options Market Predicting a Spike in Akebia Therapeutics (AKBA) Stock?
  • Zacks · 2天前
  • Edited Transcript of AKBA earnings conference call or presentation 10-Mar-20 1:00pm GMT
  • Thomson Reuters StreetEvents · 03/26 23:36
  • Akebia Therapeutics to Present Research at NKF 2020 Spring Clinical Meetings Live Virtual Conference
  • PR Newswire · 03/23 13:00

所属板块

生物技术和医学研究
-0.50%
制药与医学研究
-0.22%

热门股票

代码
价格
涨跌幅

AKBA 简况

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in developing vadadustat as an oral therapy. The Company's vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the treatment of anemia of CKD. In addition to vadadustat, the Company is engaged in developing a HIF-based portfolio of product candidates that target serious diseases of unmet need. Its portfolio includes product candidates developed internally, such as AKB-6899, as well as in-licensed product candidates, including AKB-5169. AKB-5169 is a preclinical compound in development as an oral treatment for inflammatory bowel disease (IBD).
展开

微牛提供Akebia Therapeutics Inc(NASDAQ-AKBA)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的AKBA股票新闻,以帮助您做出投资决策。